Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.03. | Evaxion Biotech: Evaxion to present at numerous upcoming conferences | 217 | GlobeNewswire (Europe) | Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months
COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:... ► Artikel lesen | |
04.03. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
25.02. | Evaxion Biotech: Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package | 300 | GlobeNewswire (Europe) | Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights... ► Artikel lesen | |
25.02. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
14.02. | Evaxion re-establishes compliance with Nasdaq minimum stockholders' equity requirement | 2 | Seeking Alpha | ||
14.02. | Evaxion secures Nasdaq listing with equity boost | 4 | Investing.com | ||
14.02. | Evaxion Biotech: Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination | 297 | GlobeNewswire (Europe) | Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders' equity requirement Evaxion has restored its equity above the minimum requirement through... ► Artikel lesen | |
EVAXION BIOTECH Aktie jetzt für 0€ handeln | |||||
12.02. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
31.01. | Evaxion Biotech: Evaxion announces closing of $10.8 million public offering | 332 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the... ► Artikel lesen | |
30.01. | Evaxion Biotech: Evaxion announces pricing of $10.8 million public offering | 327 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the... ► Artikel lesen | |
28.01. | Evaxion Biotech A/S - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
28.01. | Evaxion granted 180-day compliance extension by Nasdaq | 3 | Seeking Alpha | ||
28.01. | Evaxion Biotech: Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement | 270 | GlobeNewswire (Europe) | Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its... ► Artikel lesen | |
27.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
15.01. | Evaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-01 | 1 | RTTNews | ||
15.01. | Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 | 376 | GlobeNewswire (Europe) | Trial remains on track for completion and data readout in the second half of 2025
COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio... ► Artikel lesen | |
14.01. | Evaxion Biotech: Evaxion announces completion of ADS ratio change | 392 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today... ► Artikel lesen | |
14.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
10.01. | Evaxion Biotech: Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change | 293 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced that... ► Artikel lesen | |
07.01. | Evaxion Biotech A/S - 6-K, Report of foreign issuer | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,40 | +1,22 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech vor Geschäftszahlen mit einem Kursziel von 130 US-Dollar auf "Buy" belassen. Neuigkeiten zu der Entwicklung von... ► Artikel lesen | |
EVOTEC | 6,210 | +0,08 % | Evotec im Abwärts-Strudel: Gute News verpuffen - Kommt jetzt endlich der Rebound? | © Foto: SymbolbildEvotec hat richtig gute Neuigkeiten aus der Neurologie-Kooperation mit Bristol Myers Squibb geliefert - 20 Millionen US-Dollar Forschungszahlung, die eigentlich für frischen Wind sorgen... ► Artikel lesen | |
CUREVAC | 2,816 | -3,36 % | CureVac mit EILMELDUNG: Experten setzen BRANDNEUES Kursziel - Sofortiges HANDELN erforderlich! | ||
QIAGEN | 36,235 | +0,10 % | Biotech Report: Evotec und Qiagen rutschen ab | (shareribs.com) Frankfurt / New York 07.03.2025 - Biotech-Aktien tendierten im deutschen Handel überwiegend schwächer. Evotec und Qiagen gaben nach. An der Wall Street konnte der Sektor nicht zulegen.... ► Artikel lesen | |
PAION | 0,014 | -17,65 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
AMGEN | 287,60 | +0,42 % | Amgen: Novo Nordisk und Eli Lilly auf den Fersen - Dividende erhöht | Der Biotech-Gigant Amgen will es wissen und es mit dem Top-Duo im wachstumsstarken Markt für Adipositas-Medikamente, Novo Nordisk und Eli Lilly, aufnehmen. Der große Hoffnungsträger der US-Amerikaner... ► Artikel lesen | |
NOVAVAX | 7,414 | -0,28 % | Novavax Appoints Margaret McGlynn To Succeed James Young As Chair Of The Board | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that James Young is retiring as Chair of the Board and Margaret McGlynn has been appointed as his successor. The Company also appointed... ► Artikel lesen | |
STRYKER | 336,30 | +0,69 % | RBC Capital maintains Stryker stock Outperform rating, $435 target | ||
BIOGEN | 129,30 | +0,51 % | Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients | Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately... ► Artikel lesen | |
CRISPR THERAPEUTICS | 38,700 | -3,25 % | Crispr Therapeutics Aktie: Positive Schlagzeilen | Die Führungsriege des Gentechnik-Unternehmens Crispr Therapeutics sorgte kürzlich mit umfangreichen Aktienverkäufen für Aufsehen an der Börse. Der Vorstandsvorsitzende trennte sich von Unternehmensanteilen... ► Artikel lesen | |
OCUGEN | 0,535 | +0,56 % | Ocugen (NASDAQ:OCGN) Announces Quarterly Earnings Results, Hits Estimates | ||
MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und Liquid Biosciences machen bahnbrechende Entdeckung von mRNA-Biomarkern für die blutbasierte Erkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Vereinbarung/Sonstiges
Mainz Biomed und Liquid Biosciences machen bahnbrechende Entdeckung von mRNA-Biomarkern für die... ► Artikel lesen | |
TEMPUS AI | 42,390 | -7,08 % | Cathie Wood's ARK buys Tempus AI stock, sells Block Inc | ||
REGENCELL BIOSCIENCE | 13,570 | +208,41 % | Regencell Bioscience Stock Surges 126% | ||
SPRINGWORKS THERAPEUTICS | 50,05 | -1,01 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why |